AlphAIAlphAI — Financial news for AI agents
marketscreener.comOCT 141 min read$RVTY

JPMorgan Adjusts Price Target on Revvity to $155 From $110

JPMorgan raised its price target for Revvity from $110 to $155. TD Cowen also increased its target to $175 from $130. Revvity's stock has risen 60.29% year-to-date, trading at $155.08 at the time of the report.

Original reporting
marketscreener.com
Published Oct 14, 2026, 10:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 10:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$RVTY
Bullish
high confidence
Mentioned
$RVTY
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$RVTYBullishMed
01

Why it matters

The higher target may attract new buying interest and support the stock price.

02

Market read

Analyst target raise is a modest catalyst for Revvity, offering a short‑term trading edge.

03

What to watch

Potential execution risks in Revvity's product pipeline could temper gains.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

JPMorgan's target adjustment follows its internal valuation and earnings revision models.

Company-level read

Ticker impact

$RVTYBullishHigh confidence
Context

JPMorgan raised Revvity's price target to $155 from $110.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

The target increase reflects improved valuation expectations, prompting buying interest.

Market effects

Sector

May lift sentiment for the life‑sciences equipment sector.

Regional

Limited to U.S. markets where Revvity trades.

Global

Minimal global impact beyond Revvity and its peers.

Counterpoint

What could challenge this read

Some investors may view the target hike as already priced in, limiting upside.

Key entities

  • analyst
    JPMorgan

    Equity research firm issuing the price target change.

  • company
    Revvity

    Life‑sciences instrumentation company whose ticker is RVTY.

Read at source← All news

Related articles

SEP 9
$RVTYMed

Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery

Revvity (NYSE: RVTY) will acquire Human Cell Design (HCD), a biotech firm specializing in human cell models for metabolic diseases. The deal, expected to close in Q4 2026, will add HCD's pancreatic beta cell models to Revvity's life sciences portfolio, supporting drug discovery and preclinical research. The acquisition aims to enhance Revvity's capabilities in metabolic disease therapies, including GLP-1 and GPCR-targeting treatments. Financial terms were not disclosed.

biospace.com3 min
SEP 9
$RVTYMed

Revvity to Acquire Human Cell Design for Metabolic Disease Drug Discovery

Revvity agreed to acquire Human Cell Design, a France-based company specializing in human pancreatic beta cell models and preclinical research tools for metabolic disease drug discovery. The deal, expected to close in Q4 2026, will expand Revvity's Life Sciences portfolio, enhancing its capabilities in diabetes and obesity research. Financial terms were not disclosed. Revvity reported $2.9 billion in 2025 revenue.

citybiz.co2 min
SEP 9
$RVTYMed

RVTY Looks 8.1% Overvalued on GF Value™ as Acquisition Adds Grow

Revvity Inc (RVTY) plans to acquire Human Cell Design, a French biotech firm, to expand its life sciences portfolio. RVTY's stock is trading at $127.08, 8.1% above its GF Value™ of $117.51, indicating modest overvaluation. The company has a GF Score™ of 77/100, with strengths in momentum and profitability but weaknesses in growth. Insiders have been net sellers over the past year.

gurufocus.com2 min